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ABSTRACT
Purpose. Vitamin D deﬁciency may be an indicator of
poor prognosis in patients with breast cancer before sur-
gery. We investigated the association between serum
vitamin D concentration and breast cancer prognosis
according to intrinsic cancer subtypes.
Methods. From June to December 2006, serum 25-OHD
was measured in 310 Korean women with breast cancer
who were treated at the Asan Medical Center, Korea.
Clinicopathologic data were examined to determine the
prognostic effects of serum 25-OHD. Expression of estro-
gen receptor (ER), progesterone receptor (PR), and
epidermal growth factor receptor 2 (Her2) were measured
using tissue microarrays. Patients were classiﬁed with
luminal A, luminal B, Her2-enriched, or basal-like sub-
types of breast cancer.
Results. Mean patient age was 48.7 years, and mean
serum 25-OHD concentration was 31.4 ± 16.1 ng/ml. The
25-OHD levels were deﬁcient (\20 ng/ml) in 75 patients
(24.2%), insufﬁcient (20–29 ng/ml) in 95 (30.6%), and
sufﬁcient (30–150 ng/ml) in 140 (45.2%). Women with
deﬁcient 25-OHD levels were at increased risk of recur-
rence compared with those with sufﬁcient vitamin D levels
(P = 0.002). The 25-OHD concentration was inversely
associated with prognosis of patients with cancer of the
luminal A (P = 0.012) and luminal B subtypes
(P = 0.023), but not with the prognosis of patients with
Her2/neu-enriched (P = 0.245) or triple-negative (P =
0.879) cancer subtypes. This association remained valid
after adjustment for age, tumor size, nodal status, and
estrogen receptor status (hazards ratio = 3.97; 95% conﬁ-
dence interval = 1.77–9.61).
Conclusions. Vitamin D deﬁciency may be associated
with poor outcomes in patients with luminal-type breast
cancer.
Humans obtain vitamin D primarily by exposure of the
skin surface to ultraviolet B radiation, with small amounts
ingested from dietary sources and supplements. Vitamin D3
is activated in the body in two metabolic steps. In the ﬁrst
step, which takes place in the liver, vitamin D is converted
to its major circulating metabolite, 25-OHD3. In the second
step, occurring in the kidneys, circulating 25-OHD3 is
converted to 1a,25-(OH)2D3, the active hormonal form of
vitamin D. Another biologically active metabolite, 1,25-
(OH)2D, binds to nuclear vitamin D receptors (VDRs) in
the intestines, bone, breast, and other tissues. In vitro, 1,25-
(OH)2D has been shown to inhibit cell proliferation and to
promote apoptosis and cell differentiation in breast tumor
tissue, providing a biologic basis for an epidemiologic
study of the relationship between vitamin D concentration
and breast cancer.
1
Vitamin D concentration may be a risk and/or a valuable
prognostic factor in patients with breast cancer. Many
epidemiologic, preclinical, and clinical studies have sug-
gested that vitamin D deﬁciency may be involved in breast
cancer initiation, progression, and prognosis, whereas other
studies, including a randomized, controlled trial, showed
no such association. However, the impact of vitamin D
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adequately addressed, although one study found that
women with deﬁcient levels of vitamin D were at increased
risk of distant recurrence and death compared with women
with sufﬁcient levels of vitamin D.
2 An understanding of
the prognostic signiﬁcance of vitamin D deﬁciency in
patients with breast cancer may identify a high-risk patient
subgroup.
Ethnic/racial variations in the association of vitamin D
concentration and breast cancer also may occur. The pro-
portion of patients with breast cancer diagnosed at a
younger age is notably higher in Asian than in western
countries. Exposure to sunlight is notably lower in Asia
than in the west. Asians have a higher prevalence of milk
intolerance and use of vitamin D supplements is rare,
especially among Koreans. Apart from a Japanese study
that showed an association between vitamin D concentra-
tion and breast cancer risk, few epidemiologic efforts have
investigated such an association in Asian women.
3 We
therefore explored the prognostic signiﬁcance of vitamin D
concentration in Korean patients with breast cancer. We
also determined whether the effects of vitamin D differed
among patients with various intrinsic subtypes of breast
cancer.
PATIENTS AND METHODS
Our study protocol was approved by the Institutional
Review Board of the Asan Medical Center, Seoul, Korea.
Study Population
Patients were drawn from the Asan Medical Center
Breast Cancer Center database—a prospectively main-
tained web-based system, which includes information on
all patients who underwent surgery for breast cancer at the
Asan Medical Center since 1989. The database provides
detailed information on the type and date of breast cancer
recurrence and the date of last follow-up.
We retrospectively reviewed the outcomes of 310 Kor-
ean women who were diagnosed with breast cancer
between June and December 2006. Of these, 36 patients
had ductal carcinoma in situ (DCIS) and 261 had invasive
breast cancer. Patients were staged according to the sixth
edition of the American Joint Committee on Cancer staging
system for invasive breast cancer.
Measurements
Serum 25-OHD was measured using a radioimmunoas-
say kit (BioSource, Belgium) before surgery. Although no
consensus on optimal levels of serum 25-OHD exists,
vitamin D deﬁciency is deﬁned as\20 ng/ml (50 nmol/l).
Because an increase in average 25-OHD concentration
from 20 ng/ml to 32 ng/ml increased intestinal calcium
transport by 45–60% in women, a 25-OHD concentration
of 21–29 ng/ml (50–72 nmol/l) has been considered to be
insufﬁcient, and a level C30 ng/ml adequate. Vitamin D
intoxication is observed when serum levels of 25-OHD
exceed 150 ng/ml (374 nmol/l). As in a previous study, we
used these concentrations to sort patients.
2
Immunohistochemical Staining
Immunohistochemical staining for estrogen receptor
(ER), progesterone receptor (PR), and Her2/neu was per-
formed using arrayed tissue blocks. Brieﬂy, formalin-ﬁxed,
parafﬁn-embedded tissue sections, 5-lm thick, were
obtained using a microtome, transferred to adhesive slides,
and dried at 62C for 30 min. Sections were incubated,
using a benchmark automatic immunostaining device
(Ventana Medical Systems, Tucson, AZ), with primary
antibodies against ER (1:50 dilution; Diona, Seoul, Korea),
PR (1:100 dilution; Diona), and Her2/neu (1:250 dilution;
DAKO), followed sequentially by incubation with biotin-
ylated anti-mouse immunoglobulin and peroxidase-labeled
streptavidin, using 3.30-diaminobenzidine chromogen as
the substrate. Samples were considered positive for Her2/
neu when strong (3?) membranous staining was observed
in a least 10% of tumor cells, whereas those with staining
of grades 0 to 2? were regarded as negative.
Breast cancer samples were categorized into molecular
subtypes based on immunohistochemical proﬁles. Samples
that were ER- or PR-positive and Her2/neu-negative were
classiﬁed as luminal A, samples that were ER- or PR-
positive and Her2/neu-positive were classiﬁed as luminal
B, samples that were ER- and PR-negative and Her2/neu-
positive were classiﬁed as Her2-enriched, and samples that
were ER-, PR-, and Her2/neu-negative were classiﬁed as
triple-negative.
Statistical Analysis
Patients were classiﬁed based on serum 25-OHD con-
centration into those with sufﬁcient (30–150 ng/ml),
insufﬁcient (20–29 ng/ml), or deﬁcient (\20 ng/ml) levels
of serum 25-OHD. Disease-free survival was deﬁned as the
time from surgery to the date of the ﬁrst locoregional
recurrence, distant metastasis, detection of a secondary
primary tumor, or death from any cause. Any recurrence at
a site, including the contralateral axillary and supracla-
vicular lymph nodes, was considered a distant metastasis,
whereas recurrence in a remnant breast, the chest wall, or
the axillary or ipsilateral supraclavicular lymph node was
considered a locoregional recurrence. The v
2 test and
analysis of variance (ANOVA) were used to evaluate the
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between groups. Univariate survival was analyzed using
the Kaplan–Meier method and log-rank tests were
employed to compare survival curves. Multivariate analy-
ses were conducted using Cox’s proportional hazard
regression model. All statistical analyses were performed
by using SPSS version 12.0 (SPSS, Chicago, IL).
RESULTS
Vitamin D Levels
The mean age of the 310 patients was 48.9 ±
10.3 years, and the mean vitamin D concentration was
31.4 ± 16.1 (range, 4.8–109) ng/ml. Vitamin D levels
were deﬁcient (\20 ng/ml) in 75 patients (24.2%), insuf-
ﬁcient (20–29 ng/ml) in 95 patients (30.6%), and adequate
(30–150 ng/ml) in 140 patients (45.2%). No patient expe-
rienced vitamin D intoxication (vitamin D[150 ng/ml).
Although body mass index (BMI) was not correlated with
vitamin D concentration, patients in the adequate vitamin
D group were usually within the normal range of BMI
(Table 1).
Association of Vitamin D Levels with Tumor
Characteristics
There were no signiﬁcant correlations between vitamin
D concentration and T stage, tumor grade, or intrinsic
subtypes. Lymph node metastasis was more frequent in the
vitamin D-sufﬁcient group than in other groups
(P = 0.017; Table 1). However, when patients were sep-
arated by intrinsic tumor type, the relationship between
vitamin D level and lymph node metastasis was signiﬁcant
only for nonluminal subtypes (P = 0.008) and not for
luminal types of breast cancer (P = 0.217).
Prognostic Associations of Vitamin D Level
Of our 310 patients, 31 (10%) experienced metastasis
and 9 (2.9%) died after a median follow-up time of
23 months. Of these nine patients, two died without doc-
umented spread of breast cancer.
We found that vitamin D concentration was a signiﬁcant
predictor of disease-free survival. Women with sufﬁcient
levels of vitamin D had signiﬁcantly better disease-free
survival than women with deﬁcient levels (P = 0.002;
Fig. 1). Of the ﬁve patients who developed a second pri-
mary cancer, four had deﬁcient concentrations of vitamin D
(P = 0.012; Table 2). One patient who had sufﬁcient
concentrations of vitamin D had pancreas cancer
19 months after breast cancer diagnosis.
TABLE 1 Clinicopathologic and treatment-related factors in the
three 25-OHD groups
Deﬁcient Insufﬁcient Sufﬁcient P value
No. % No. % No. %
Mean age
(years)
48.7 (?10.3) 47.8 (?9.4) 49.6 (?10.8) 0.409
Mean tumor
size (cm)
1.8 ?1.6 2 ?1.6 2.1 ?1.6 0.449
BMI (kg/m
2) 0.087
B25 65 86.7 76 80 99 70.7
25–30 8 10.7 17 17.9 34 24.3
[30 2 2.7 2 2.1 7 5
T stage 0.18
T0 8 10.7 13 13.7 12 8.6
T1 43 57.3 46 48.4 68 48.6
T2 21 28 28 29.5 56 40
T3 3 4 8 8.4 4 2.9
LN metastasis 0.017
Negative 48 64 63 66.3 69 49.3
Positive 27 36 32 33.7 71 50.7
Grade 0.136
Low (1–2) 36 54.5 50 61 88 68.8




Luminal A 34 45.9 46 49.5 61 43.6
Luminal B 19 25.7 23 24.7 35 25
Her2/neu
enriched
7 9.5 17 18.3 26 18.6
Triple
negative
14 18.9 7 7.5 18 12.9
FIG. 1 Univariate analysis of disease-free survival according to
vitamin D status
1832 H. J. Kim et al.Vitamin D status was prognostic in patients with breast
cancer of luminal types A and B but not in patients with
triple-negative or Her2/neu-enriched cancer subtypes. No
evidence could be adduced to indicate that the prognostic
effects of vitamin D were related to Her2/neu status
(Fig. 2). In patients with luminal types of breast cancer,
deﬁcient concentrations of vitamin D were associated with
signiﬁcantly lower disease-free survival times (P = 0.004).
This association was not observed in patients with nonlu-
minal types of breast cancer (P = 0.475; Fig. 3).
Multivariate analysis, after adjusting for age, LN posi-
tivity, ER status, and T stage, showed that a deﬁcient level
of vitamin D was an independent prognostic indicator of
breast cancer recurrence (hazards ratio (HR) 3.97; 95%
conﬁdence interval (CI) = 1.76–8.91; Table 3).
DISCUSSION
We have shown that deﬁcient serum concentrations of
vitamin D were signiﬁcantly associated with an increased
risk of distant recurrence of breast cancer compared with
patients who had adequate levels of vitamin D. Further-
more, the prognostic association varied with intrinsic
subtype—signiﬁcant only for patients with luminal types of
breast cancer. To the best of our knowledge, the present
study is the ﬁrst to show that vitamin D concentration is a
valuable prognostic indicator in estimation of survival,
depending on breast cancer intrinsic subtype.
Although several epidemiologic studies have evaluated
associations between vitamin D concentration, breast can-
cer risk, and prognosis, the cited works have yielded
inconsistent results.
4 Among methodologic inconsistencies
evident in these studies are evaluation of vitamin D status;
some works assessed the effects of dietary or supplemental
intake of vitamin D and others explored vitamin D status
TABLE 2 Nonbreast second malignancies in the three 25-OHD
groups
Deﬁcient Insufﬁcient Sufﬁcient P value
No. % No. % No. %
Nonbreast second
malignancies
4 5.3 0 0 1 0.7 0.012
FIG. 2 Disease-free survival and vitamin D status with respect to intrinsic breast cancer subtype. a Luminal A. b Luminal B. c Her2/neu-
enriched. d Triple-negative
Vitamin D Deﬁciency as a Risk Factor for Breast Cancer Recurrence 1833with respect to sunlight exposure. Measurement of circu-
lating concentrations of 25-OHD provides an integrated
measure of vitamin D derived from all sources, including
sunlight exposure, diet, and supplementation, and is con-
sidered the best indicator of vitamin D body stores.
5–7 The
cited epidemiologic studies also used different categori-
zations of vitamin D status, and one work, similar to the
present report, categorized vitamin D status by serum 25-
OHD concentration as deﬁcient, insufﬁcient, and
sufﬁcient.
2
Several epidemiologic studies have shown conﬂicting
results between vitamin D and hormone receptor-deﬁned
breast cancer. Increased intake of vitamin D was found to
be consistently associated with a signiﬁcantly reduced risk
of ER?/PR? tumors, and dietary vitamin D level was
inversely related to the risk of ER? tumors.
8,9 A recent
Japanese study reported that ER? and/or PR?/Her2-
breast cancer frequency was signiﬁcantly associated with
vitamin D intake in premenopausal women.
3 In contrast,
the Iowa Women’s health study found an inverse, but
statistically insigniﬁcant, association between high vitamin
D intake and ER- or PR-type tumors.
10 A case series
showed that the triple-negative breast cancer phenotype
was associated with the lowest average serum vitamin D
concentration and the highest percentage of vitamin D-
deﬁcient patients.
11 However, the cited study included
fewer patients with the triple-negative phenotype (N = 15)
than were evaluated in the present work (N = 39).
In this study, we found that vitamin D level was prog-
nostic in all patients with breast cancer, but the
concentration was not signiﬁcantly prognostic in patients
with triple-negative and Her2/neu-enriched subtypes. One
plausible explanation is that vitamin D acts synergistically
to suppress the effects of estrogen in patients with luminal-
type breast cancer. The antiproliferative and antitumor
effects of vitamin D on estrogen-responsive breast cancer
cells are mediated by disruption of estrogen mitogenic and
survival signals. A potential vitamin D receptor element has
been identiﬁed within the ER promoter gene, suggesting
that 1,25-(OH)2D3 may directly regulate ER gene tran-
scription.
12 Vitamin D reduces the expression and
biological activity of prostaglandins and decreases synthe-
sis of aromatase, in addition to suppressing the proliferative
activity of 17ß-estradiol and downregulating the level of the
estrogen receptor.
13,14 Moreover, higher concentrations of
25-(OH)D have been shown to signiﬁcantly lower serum
luteal progesterone and estrogen levels. This may represent
a mechanism by which higher 25-(OH)D levels in young
women may reduce subsequent breast cancer risk.
15 Fur-
thermore, sensitivity to 1,25-(OH) D3 is generally higher in
breast cancer cells that express estrogen receptor than in
cells that do not synthesize the protein.
16,17
FIG. 3 Disease-free survival and vitamin D status in a hormone receptor-positive and b hormone receptor-negative patients
TABLE 3 Results of Cox proportional hazard regression modeling
according to 25 OHD status
Characteristic Weight category Disease-free survival
HR 95% CI P value
Vitamin D Sufﬁcient Reference
Insufﬁcient 0.82 0.28–2.37 0.711
Deﬁcient 3.97 1.77–8.91 0.001
Age (years) 1.01 0.98–1.04 0.535
LN positivity 4.18 1.8–9.72 0.001
ER negativity 1.88 0.9–3.9 0.093
Tumor size (cm) 1.12 0.95–1.33 0.19
1834 H. J. Kim et al.Vitamin D has been associated with breast cancer
metastasis and drug response. Vitamin D has been shown
to inhibit invasion and metastasis by reducing the activity
of MMP-9, UPA, and TPA, and by increasing the levels of
PA inhibitor 1, MMP inhibitor 1, and general antiangio-
genic activity.
14 Moreover 1,25-(OH)2D3 has been shown
to enhance the sensitivity of breast cancer cells to several
anticancer drugs and other agents. Vitamin D compounds
have been demonstrated to potentiate apoptosis induced by
adriamycin, Taxol, radiation, and tamoxifen.
18–20 These
ﬁndings indicate that maintenance of adequate vitamin D
concentrations during adjuvant treatment may enhance the
effects of such treatment and prolong survival.
We found that patients with vitamin D deﬁciency
developed signiﬁcantly more frequent second primary
cancers than did patients with sufﬁcient vitamin D con-
centration. Vitamin D deﬁciency also has been associated
with an increased risk of Hodgkin‘s lymphoma as well as
colon, prostate, ovarian, breast, and other cancers.
21 Sec-
ondary cancers are among the most threatening long-term
health problems in patients with breast cancer. Moreover,
some breast cancer treatment regimens are associated with
an increased risk of osteoporosis, which also can be caused
by vitamin D deﬁciency. Such deﬁciency has been asso-
ciated with an increased level of depression and overall
mortality in the general population.
22 Therefore, correction
of vitamin D status may be important not only for survival
but to improve quality of life in patients with breast cancer.
One study, in which patients who received adjuvant che-
motherapy were prescribed vitamin D3 at 400 IU for
1 year found that fewer than 15% of such patients achieved
sufﬁcient 25-OHD levels, indicating that the currently
recommended doses of vitamin D are not adequate to
positively affect bone health or to improve survival.
7
Safety is an important consideration when recommending
nutrient intake. Vitamin D intoxication is extremely rare
but can be caused by inadvertent or intentional ingestion of
excessively high doses.
23 However, a recent review found
no reports of toxicity in patients taking\20,000 IU per day
of vitamin D or in those with a serum 25-OHD concen-
tration\200 ng/ml during an extended period.
24
Differences in the prevalence of vitamin D insufﬁ-
ciency have been associated with various factors,
including age, race, BMI, exposure to sun, geographic
location, dietary vitamin D intake, daily activity, and
exercise level. Korea lies at latitudes of 33–43 degrees
north and thus is considered to enjoy abundant sunlight.
Oriental culture, however, does not encourage exposure of
skin to the sun, especially in women.
25,26 Moreover, milk
intolerance is more prevalent in Koreans than in western
populations. Although deﬁcient vitamin D status has been
associated with obesity in western women, we found no
such relationship among our patients. The relationship
between BMI and fat levels in Asian women differs sig-
niﬁcantly from that in white females.
27,28 Although a
previous study reported that 92% of Korean women had
vitamin D concentrations \75 nmol/l, vitamin D status
improved after patients were educated on the importance
of vitamin D ingestion and dietary supplementation.
Furthermore, exercise can increase serum 25-OHD con-
centrations.
29 These ﬁndings indicate that vitamin D
deﬁciency can be overcome by education, lifestyle mod-
iﬁcation, and dietary supplementation regardless of racial
differences.
Our ﬁndings also indicate the importance of prospective,
randomized studies to determine vitamin D concentrations
that can predict the outcomes of patients with breast can-
cer, as well as the level of vitamin D supplementation
required by vitamin D-deﬁcient patients. Randomized
studies are required to determine the effects of increasing
vitamin D levels on cancer risk and prognosis. The size and
duration of cancer prevention trials, along with intrinsic
problems in long-term adherence to assigned protocols,
may limit the ability of such efforts to address many
important questions, especially those related to behavioral
changes. Therefore, patients with breast cancer should be
educated on lifestyle changes, including exposure to sun-
light, eating habits, and dietary supplementation that may
prolong survival. Moreover, vitamin D concentrations
should be measured regularly, and, if necessary, such
patients should be given vitamin D supplements.
The present study had several limitations. Vitamin D
concentration was measured only before surgery and not
during follow-up. Adjuvant chemotherapy has been found
to reduce plasma vitamin D concentration signiﬁcantly.
30
Therefore, the prognostic signiﬁcance of changes in vita-
min D status, especially in vitamin D-deﬁcient patients,
remains to be determined. Circulating concentrations of
vitamin D should be measured in all patients with breast
cancer, not only before commencement of treatment but
also during adjuvant procedures, and during follow-up
periods. Second, because all patients of the present study
were of Korean nationality, thus all ethnically homoge-
neous Far East Asians, we cannot state whether our results
can be applied to other ethnic groups and countries.
In conclusion, our ﬁndings suggest that deﬁcient vitamin
D status is a high-risk factor for recurrence in patients with
breast cancer, especially those with hormone receptor-
positive breast cancer. These observational ﬁndings may
beneﬁt patients with hormone receptor-positive breast
cancer by encouraging dietary supplementation to maintain
adequate vitamin D levels. Vitamin D status should be
measured during follow-up to optimize patient outcomes
and reduce mortality.
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